Abstract
Lipopolysaccharide (LPS), which constitutes the lipid portion of the outer leaflet of Gram-negative bacteria, is essential for growth. It is also responsible for the variety of biological effects associated with Gram-negative sepsis. Recent advances have elucidated the exact chemical structure of this highly complex macromolecule and much of the enzymology involved in its biosynthesis.
Enzymes involved in LPS biogenesis are optimal targets for the development of novel therapeutics since they are sufficiently conserved among diverse, clinically-relevant bacteria and no analogue counterpart is present in humans. During the last thirty years a number of inhibitors of LPS biosynthesis have been developed: some of these compounds have antibacterial properties, while others show excellent in vitro activity and are undergoing further investigation. The main focus of this review will be the biology of LPS in bacteria summarizing the knowledge about structure and enzymatic catalysis, as well as chemical efforts towards the synthesis of inhibitors of the key enzymes involved in the biosynthesis of Kdo, toward the minimal conserve structure Kdo2-LipA. In addition, very recent advances in deciphering the molecular mechanisms of LPS transport to the cell surface, as a new target to develop novel antibacterials, will be reported. Future directions and perspectives will also be outlined.
Keywords: LPS, OM biogenesis, enzyme inhibitors, Kdo, Lipid A, Gram-negative bacteria, antibiotics, enzyme structure, pathogenic microorganisms, Kdo2-LipA, antibacterials
Current Medicinal Chemistry
Title: New Targets for Antibacterial Design: Kdo Biosynthesis and LPS Machinery Transport to the Cell Surface
Volume: 18 Issue: 6
Author(s): L. Cipolla, A. Polissi, C. Airoldi, L. Gabrielli, S. Merlo and F. Nicotra
Affiliation:
Keywords: LPS, OM biogenesis, enzyme inhibitors, Kdo, Lipid A, Gram-negative bacteria, antibiotics, enzyme structure, pathogenic microorganisms, Kdo2-LipA, antibacterials
Abstract: Lipopolysaccharide (LPS), which constitutes the lipid portion of the outer leaflet of Gram-negative bacteria, is essential for growth. It is also responsible for the variety of biological effects associated with Gram-negative sepsis. Recent advances have elucidated the exact chemical structure of this highly complex macromolecule and much of the enzymology involved in its biosynthesis.
Enzymes involved in LPS biogenesis are optimal targets for the development of novel therapeutics since they are sufficiently conserved among diverse, clinically-relevant bacteria and no analogue counterpart is present in humans. During the last thirty years a number of inhibitors of LPS biosynthesis have been developed: some of these compounds have antibacterial properties, while others show excellent in vitro activity and are undergoing further investigation. The main focus of this review will be the biology of LPS in bacteria summarizing the knowledge about structure and enzymatic catalysis, as well as chemical efforts towards the synthesis of inhibitors of the key enzymes involved in the biosynthesis of Kdo, toward the minimal conserve structure Kdo2-LipA. In addition, very recent advances in deciphering the molecular mechanisms of LPS transport to the cell surface, as a new target to develop novel antibacterials, will be reported. Future directions and perspectives will also be outlined.
Export Options
About this article
Cite this article as:
Cipolla L., Polissi A., Airoldi C., Gabrielli L., Merlo S. and Nicotra F., New Targets for Antibacterial Design: Kdo Biosynthesis and LPS Machinery Transport to the Cell Surface, Current Medicinal Chemistry 2011; 18 (6) . https://dx.doi.org/10.2174/092986711794927676
DOI https://dx.doi.org/10.2174/092986711794927676 |
Print ISSN 0929-8673 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-533X |
Call for Papers in Thematic Issues
Advances in Medicinal Chemistry: From Cancer to Chronic Diseases.
The broad spectrum of the issue will provide a comprehensive overview of emerging trends, novel therapeutic interventions, and translational insights that impact modern medicine. The primary focus will be diseases of global concern, including cancer, chronic pain, metabolic disorders, and autoimmune conditions, providing a broad overview of the advancements in ...read more
Cellular and Molecular Mechanisms of Non-Infectious Inflammatory Diseases: Focus on Clinical Implications
The Special Issue covers the results of the studies on cellular and molecular mechanisms of non-infectious inflammatory diseases, in particular, autoimmune rheumatic diseases, atherosclerotic cardiovascular disease and other age-related disorders such as type II diabetes, cancer, neurodegenerative disorders, etc. Review and research articles as well as methodology papers that summarize ...read more
Chalcogen-modified nucleic acid analogues
Chalcogen-modified nucleosides, nucleotides and oligonucleotides have been of great interest to scientific research for many years. The replacement of oxygen in the nucleobase, sugar or phosphate backbone by chalcogen atoms (sulfur, selenium, tellurium) gives these biomolecules unique properties resulting from their altered physical and chemical properties. The continuing interest in ...read more
Current advances in inherited cardiomyopathy
Describe in detail all novel advances in multimodality imaging related to inherited cardiomyopathy diagnosis and prognosis. Shed light to deeper phenotypic characterization. Acknowledge recent advances in genetics, genomics and precision medicineread more
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
MicroRNA and Exosome in Retinal-related Diseases: Their Roles in the
Pathogenesis and Diagnosis
Combinatorial Chemistry & High Throughput Screening Non Peptidic Ligands at the Opioid Receptor Like-1 (ORL-1)
Mini-Reviews in Medicinal Chemistry Clinical Aspects of Melatonin in the Acute Coronary Syndrome
Current Vascular Pharmacology The Crosstalk between Gut Inflammation and Gastrointestinal Disorders During Acute Pancreatitis
Current Pharmaceutical Design Current Approaches to Drug Discovery for Chagas Disease: Methodological Advances
Combinatorial Chemistry & High Throughput Screening A Review on Coronavirus Disease- A Future Challenge for Mankind (Focusing on Indian Situation)
Coronaviruses The Family B1 GPCR: Structural Aspects and Interaction with Accessory Proteins
Current Drug Targets In Silico Study of Structural and Geometrical Requirements of Natural Sesquiterpene Lactones with Trypanocidal Activity
Mini-Reviews in Medicinal Chemistry Phosphodiesterase 10 Inhibitors: New Disease Modifying Drugs for Parkinson’s Disease?
Current Medicinal Chemistry The State of the Art of Pyrazole Derivatives as Monoamine Oxidase Inhibitors and Antidepressant/Anticonvulsant Agents
Current Medicinal Chemistry Subject Index to Volume 3
Current Medicinal Chemistry - Anti-Infective Agents Biology and Clinical Management of Myeloproliferative Neoplasms and Development of the JAK Inhibitor Ruxolitinib
Current Medicinal Chemistry Patent Selections
Recent Patents on Computer Science Synthesis and Anti-Paracoccidioides Activity of Calix[n]arenes
Letters in Drug Design & Discovery Suicide and Genetic Biomarkers: Toward Personalized Tailored-treatment with Lithium and Clozapine
Current Pharmaceutical Design Small Molecule Approaches Toward the Non-Microbicidal Modulation of Bacterial Biofilm Growth and Maintenance
Anti-Infective Agents in Medicinal Chemistry The Challenges of Dealing with Promiscuous Drug-Metabolizing Enzymes, Receptors and Transporters
Current Drug Metabolism COVID-19 Mortality and the Cytokine Storm: An Added Value for APOE Genotyping
Coronaviruses Discovery of Novel CK2 Leads by Cross-Docking Based Virtual Screening
Medicinal Chemistry TGF-Beta Type I Receptor (Alk5) Kinase Inhibitors in Oncology
Current Pharmaceutical Biotechnology